240 related articles for article (PubMed ID: 35800183)
21. [Primary sclerosing cholangitis : Current diagnostics and treatment].
Liwinski T; Schramm C
Internist (Berl); 2018 Jun; 59(6):551-559. PubMed ID: 29700559
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin G4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma diagnosed with following bile duct resection: report of a case.
Miki A; Sakuma Y; Ohzawa H; Sanada Y; Sasanuma H; Lefor AT; Sata N; Yasuda Y
Int Surg; 2015 Mar; 100(3):480-5. PubMed ID: 25785331
[TBL] [Abstract][Full Text] [Related]
23. Primary sclerosing cholangitis.
Silveira MG; Lindor KD
Can J Gastroenterol; 2008 Aug; 22(8):689-98. PubMed ID: 18701947
[TBL] [Abstract][Full Text] [Related]
24. [A contribution to the differential diagnostics of sclerosing cholangitides].
Blaho M; Dítě P; Bojková M; Rydlo M; Kupka T; Svoboda P; Klvaňa P; Martínek A
Vnitr Lek; 2017; 63(1):50-55. PubMed ID: 28225291
[TBL] [Abstract][Full Text] [Related]
25. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
Rizvi S; Yang JD; Gores GJ
Gut; 2017 Jan; 66(1):4-5. PubMed ID: 27587361
[No Abstract] [Full Text] [Related]
26. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
27. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.
Schwarze C; Terjung B; Lilienweiss P; Beuers U; Herzog V; Sauerbruch T; Spengler U
Clin Exp Immunol; 2003 Aug; 133(2):283-9. PubMed ID: 12869036
[TBL] [Abstract][Full Text] [Related]
28. Primary sclerosing cholangitis: diagnosis, prognosis, and management.
Singh S; Talwalkar JA
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):898-907. PubMed ID: 23454027
[TBL] [Abstract][Full Text] [Related]
29. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.
Vesterhus M; Karlsen TH
J Gastroenterol; 2020 Jun; 55(6):588-614. PubMed ID: 32222826
[TBL] [Abstract][Full Text] [Related]
30. Recent insights in primary sclerosing cholangitis.
Ponsioen CY
J Dig Dis; 2012 Jul; 13(7):337-41. PubMed ID: 22713082
[TBL] [Abstract][Full Text] [Related]
31. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
32. Management of primary sclerosing cholangitis.
Björnsson E
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):163-72. PubMed ID: 19305376
[TBL] [Abstract][Full Text] [Related]
33. Primary sclerosing cholangitis in children versus adults: lessons for the clinic.
Adike A; Carey EJ; Lindor KD
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):1025-1032. PubMed ID: 30199272
[TBL] [Abstract][Full Text] [Related]
34. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.
Goss JA; Shackleton CR; Farmer DG; Arnaout WS; Seu P; Markowitz JS; Martin P; Stribling RJ; Goldstein LI; Busuttil RW
Ann Surg; 1997 May; 225(5):472-81; discussion 481-3. PubMed ID: 9193175
[TBL] [Abstract][Full Text] [Related]
35. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
36. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.
Sowa M; Kolenda R; Baumgart DC; Pratschke J; Papp M; Tornai T; Suchanski J; Bogdanos DP; Mytilinaiou MG; Hammermann J; Laass MW; Conrad K; Schramm C; Franke A; Roggenbuck D; Schierack P
Front Immunol; 2018; 9():1959. PubMed ID: 30233574
[No Abstract] [Full Text] [Related]
37. Cholangiocarcinoma in patients with primary sclerosing cholangitis.
Fung BM; Tabibian JH
Curr Opin Gastroenterol; 2020 Mar; 36(2):77-84. PubMed ID: 31850928
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
Taghavi SA; Eshraghian A; Niknam R; Sivandzadeh GR; Bagheri Lankarani K
Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):575-584. PubMed ID: 29781738
[TBL] [Abstract][Full Text] [Related]
39. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis.
Bergquist A; Broomé U
Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):643-56. PubMed ID: 11492973
[TBL] [Abstract][Full Text] [Related]
40. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases.
Muratori P; Muratori L; Guidi M; Maccariello S; Pappas G; Ferrari R; Gionchetti P; Campieri M; Bianchi FB
Clin Exp Immunol; 2003 Jun; 132(3):473-6. PubMed ID: 12780695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
